• Aucun résultat trouvé

[PDF] Top 20 Acarbose for type 2 diabetes prevention.

Has 10000 "Acarbose for type 2 diabetes prevention." found on our website. Below are the top 20 most common "Acarbose for type 2 diabetes prevention.".

Acarbose for type 2 diabetes prevention.

Acarbose for type 2 diabetes prevention.

... of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, B-4000 Liège, Belgium Sir—Jean-Louis Chiasson and colleagues (June 15, p 2072) 1 report that after a mean follow-up of 3 ... Voir le document complet

1

An integrated approach for the identification of predictive markers of type 2 diabetes

An integrated approach for the identification of predictive markers of type 2 diabetes

... need for more accurate assessment of the inputs and their consequences to health (Panagiotou, ...of type 2 diabetes ...compared for several parameters (clinical, biochemical parameters, ... Voir le document complet

2

Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.

Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.

... variant for rs553668 is likely to cause defective insulin secretion in human pancreatic islets because of an overexpression of ADRA2A ...in type 2 diabetes ...of type 2 ... Voir le document complet

5

Which incretin-based therapy for type 2 diabetes?

Which incretin-based therapy for type 2 diabetes?

... GLP-1 RAs - exenatide LAR, dulaglutide, semaglutide, albiglutide -) with a placebo in patients with type 2 diabetes and a high cardiovascular risk profile. Although none of these trials will provide ... Voir le document complet

7

SGLT2 versus DPP4 inhibitors for type 2 diabetes.

SGLT2 versus DPP4 inhibitors for type 2 diabetes.

... Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized ...considerations for the treatment of ... Voir le document complet

6

The endocannabinoid system: a promising target for the management of type 2 diabetes.

The endocannabinoid system: a promising target for the management of type 2 diabetes.

... with type 2 diabetes which are strongly associated with insulin resistance ...strategy for the treatment of liver fibrosis ...of type 2 diabetes ... Voir le document complet

49

Sexually dimorphic roles for the type 2 diabetes-associated C2cd4b gene in murine glucose homeostasis.

Sexually dimorphic roles for the type 2 diabetes-associated C2cd4b gene in murine glucose homeostasis.

... variant for type 2 diabetes risk at this locus [ 9 ...the diabetes risk variant rs7163757 [ 9 ] and whether it may play a role in gene expres- sion in disease-relevant tissues (notably ... Voir le document complet

15

‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?

‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?

... ‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice? Despite being a common feature in clinical practice and a major challenge for healthcare providers involved ... Voir le document complet

3

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

... Diabetes & Metabolism 40 (2014) S1-S3 Type 2 diabetes is among the most important and preva- lent chronic diseases, and any novel therapy that is able to address chronic hyperglycaemia is ... Voir le document complet

3

Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women.: Job Strain and Incident Type 2 Diabetes

Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women.: Job Strain and Incident Type 2 Diabetes

... incident type 2 diabetes, with investigators masked to outcome information ...incident type 2 diabetes The outcome was the first record of type 2 diabetes, ... Voir le document complet

27

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

... Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, et al... Tar- geting the AMPK pathway for the treatment of Type 2 diabetes...[r] ... Voir le document complet

3

Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?

Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?

... of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liège, ...the Diabetes Prevention Program (DPP) showed that withdrawal of metformin for 1-2 ... Voir le document complet

4

Pharmacological prevention of type 2 diabetes.

Pharmacological prevention of type 2 diabetes.

... for the prevention of type 2 diabetes in high-risk individuals, especially those with IGT ...on diabetes incidence in patients with IGT or high-normal/elevated fasting glucose ... Voir le document complet

46

Voglibose for prevention of type 2 diabetes mellitus.

Voglibose for prevention of type 2 diabetes mellitus.

... al, for the NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired ... Voir le document complet

3

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

... 3.1 Effect of atorvastatin on lipid and glucose metabolism 3.1.1 Atorvastatin and lipid profile Atorvastatin is a potent synthetic HMG-CoA reductase inhibitor, which explains most of its metabolic and protective ... Voir le document complet

15

Type 2 Diabetes Remission After Gastric Bypass: What Is the Best Prediction Tool for Clinicians?

Type 2 Diabetes Remission After Gastric Bypass: What Is the Best Prediction Tool for Clinicians?

... These models appeared to provide relatively good prediction errors between 12 and 16% [9,10], but only poorly predicted T2D remission one year after RYGB surgery in our cohort of 84 French diabetic obese subjects. This ... Voir le document complet

22

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.

... The safety profiles of DPP-4i [7] and SGLT2i [9] are well known. The safety profile of the DPP-4i-SGLT2i combination is comparable with that of each component prescribed separately. DPP-4i are generally well tolerated ... Voir le document complet

37

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

... therapy for most individuals. [2-4] Second-line agents are diverse and increasingly ...cotransporter type 2 (SGLT2) inhibitors (gliflozins), [6] glucagon-like peptide-1 receptor agonists ... Voir le document complet

32

Preventing and treating kidney disease in patients with type 2 diabetes

Preventing and treating kidney disease in patients with type 2 diabetes

... marker, for instance reduction in albuminuria, but not clinical events of true relevance to T2DM patients, for instance need for renal replacement ...care for T2DM patients at risk of CKD [ ... Voir le document complet

19

Skin autofluorescence predicts cancer in subjects with type 2 diabetes

Skin autofluorescence predicts cancer in subjects with type 2 diabetes

... complicated type 2 ...χ 2 : p=0.001). By Cox regression analysis adjusted for age, gender, body mass index, history of smoking and renal parameters, skin autofluorescence ... Voir le document complet

8

Show all 10000 documents...